Results 31 to 40 of about 357,544 (339)
miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. [PDF]
PLoS ONE, 2014 Non-small-cell lung cancer (NSCLC) is one of the most leading causes of cancer-related deaths worldwide. Paclitaxel based combination therapies have long been used as a standard treatment in aggressive NSCLCs.
Abhisek Chatterjee +2 more
doaj +1 more source
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship [PDF]
, 2007 We undertook a systematic review of the pre-clinical and clinical literature for studies investigating the relationship between platinum and taxane resistance.
Davey, Ross +2 more
core +1 more source
Pathomechanisms of Paclitaxel-Induced Peripheral Neuropathy
Toxics, 2021 Peripheral neuropathy is one of the most common side effects of chemotherapy, affecting up to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces neuropathy in up to 97% of all gynecological and urological cancer patients.
Ines Klein, H. Lehmann
semanticscholar +1 more source
Traditional Chinese medicine herbal mixture LQ arrests FUCCI-expressing HeLa cells in G₀/G₁ phase in 2D plastic, 2.5D Matrigel, and 3D Gelfoam culture visualized with FUCCI imaging. [PDF]
, 2015 We used the fluorescence ubiquitination-based cell cycle indicator (FUCCI) to monitor cell cycle arrest after treatment of FUCCI-expressing HeLa cells (FUCCI-HeLa) with a traditional Chinese medicine (TCM) herbal mixture LQ, previously shown to have anti-
Bouvet, Michael +4 more
core +2 more sources
Understanding cisplatin resistance using cellular models [PDF]
, 2007 Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, Mary W., Stordal, Britta
core +2 more sources
Gastric Cancer, 2021 Background In the phase 3 KEYNOTE-061 study (cutoff: 10/26/2017), pembrolizumab did not significantly prolong OS vs paclitaxel as second-line (2L) therapy in PD-L1 combined positive score (CPS) ≥ 1 gastric/GEJ cancer.
C. Fuchs +19 more
semanticscholar +1 more source
Paclitaxel Induces Acute Pain via Directly Activating Toll like Receptor 4
Molecular Pain, 2015 Paclitaxel, a powerful anti-neoplastic drug, often causes pathological pain, which significantly reduces the quality of life in patients. Paclitaxel-induced pain includes pain that occurs immediately after paclitaxel treatment (paclitaxel-associated ...
Xisheng Yan +6 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: Drug resistance is a major obstacle in chemotherapy for ovarian cancer, wherein the up regulation of drug-resistant genes plays an important role.
Yaqing Zhang +6 more
doaj +1 more source
Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice [PDF]
, 2018 Elevated N-methyl-D-aspartate receptor (NMDAR) activity is linked to central sensitization and chronic pain. However, NMDAR antagonists display limited therapeutic potential because of their adverse side effects. Novel approaches targeting the NR2B-PSD95-
Chawla, Aarti +6 more
core +1 more source
Journal of Pharmacological Sciences, 2012 Peripheral neuropathic pain is a serious side effect of paclitaxel treatment. However, the mechanism of this paclitaxel-induced neuropathic pain is unknown. In this study, we investigated the effects of paclitaxel on the voltage-dependent calcium channel
Kazuyoshi Kawakami +7 more
doaj +1 more source